Calcium channel blocker use and risk of Parkinson's disease.
We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow-Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73-1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD.
Simon
Kelly Claire
KC
Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA. ksimon@hsph.harvard.edu
Gao
Xiang
X
Chen
Honglei
H
Schwarzschild
Michael A
MA
Ascherio
Alberto
A
D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D009726:Nurses; D010300:Parkinson Disease / Q000209:etiology*; D016016:Proportional Hazards Models; D012306:Risk
D002121:Calcium Channel Blockers